Membranous Nephropathy Clinical Trial
Official title:
PLA2R Autoreactive B-Cell Subsets and Immune Cell Monitoring in Membranous Nephropathy: Identification of Outcome Predictors and Novel Insights Into Disease Pathogenesis
Membranous nephropathy (MN) is the most frequent cause of nephrotic syndrome (NS) in adults. The majority of MN patients show detectable circulating antibodies against the M-type phospholipase A2 receptor (PLA2R). Infusion of anti-CD20 monoclonal antibodies results in a profound depletion of B-cells, which are thought to be responsible for anti-PLA2R production. B-cell depletion is followed by NS remission in 70% of cases. Limited evidence highlighted that differences in the B- and T-cell compartments may exist between responders and non-responders. Owing to the non-homogenous efficacy of anti-CD20 treatment, investigators hypothesize that in MN patients who experience NS remission after B-cell depleting therapy, autoreactive B-cells may be mostly circulating, whereas in patients who do not respond to the same treatment, autoreactive B-cells may chiefly reside into secondary lymphoid organs - and thus be more resistant to the drug action. Researchers will therefore extensively analyze the circulating immune repertoire of MN patients before and after the infusion of B-cell lineage depleting agents, assessing the presence of circulating PLA2R autoreactive B cells from appropriately stratified responder and non-responder patients. Patients and healthy controls will be enrolled in this study. Patients will be stratified according to gender, anti-PLA2R status, type of B-cell lineage depleting agent received and response to treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT06341205 -
Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX)
|
Phase 3 | |
| Active, not recruiting |
NCT04893096 -
MOR202 for Refractory MN
|
Phase 2 | |
| Completed |
NCT00405340 -
Rituximab in the Treatment of Idiopathic Membranous Nephropathy
|
Phase 0 | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Active, not recruiting |
NCT04652570 -
Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03929887 -
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
|
||
| Active, not recruiting |
NCT03949855 -
Belimumab With Rituximab for Primary Membranous Nephropathy
|
Phase 2 | |
| Not yet recruiting |
NCT06242327 -
An Outcome Analysis of Primary Membranous Nephropathy
|
||
| Completed |
NCT00983034 -
The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy
|
N/A | |
| Completed |
NCT03025828 -
Adrenocorticotropic Hormone in Membranous Nephropathy
|
Phase 4 | |
| Recruiting |
NCT05732402 -
An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT04571658 -
NEPTUNE Match Study
|
||
| Active, not recruiting |
NCT05894512 -
Analysis of T- and B-Cell Subpopulations in Membranous Nephropathy
|
||
| Not yet recruiting |
NCT05941845 -
Interferon Alfa Therapy Based on Th17 Profile in Membranous Nephropathy
|
Phase 2 | |
| Completed |
NCT00518219 -
To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN)
|
Phase 4 | |
| Completed |
NCT02199145 -
Role of Anti-mouse PLA2R1 ELISA in Membranous Nephropathy
|
N/A | |
| Not yet recruiting |
NCT04326218 -
Immunopathological Analysis in a French National Cohort of Membranous Nephropathy
|
N/A | |
| Active, not recruiting |
NCT03453619 -
Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
|
Phase 2 | |
| Completed |
NCT01955187 -
Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy
|
Phase 3 | |
| Completed |
NCT04733040 -
Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)
|
Phase 2 |